Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a $40bn valuation by 2040.

However, technical hurdles in the field remain. This month's cover feature analyses the key challenges and reflects on the way forward for ADC research and development.

Also in this issue, we look at the makeup of the next wave of obesity drugs, US pharma Insmed's new UK site, and how the new US-EU trade deal on tariffs signifies the end of pharma’s geopolitical immunity.

Don't miss our exclusive interview with Dr. Mariana Socal on the impact of Trump's tariffs on pharma.

Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.